{"title":"Automated verification of citation support and reference accuracy: a pilot evaluation of CiteWell.","authors":"Paul Sebo, Ting Wang","doi":"10.1016/j.ejim.2026.107280","DOIUrl":"https://doi.org/10.1016/j.ejim.2026.107280","url":null,"abstract":"","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":" ","pages":"107280"},"PeriodicalIF":8.1,"publicationDate":"2026-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149418454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gretchen E Maurer, Wen-Jan Tuan, Alexandra Evans, Katherine S Chu, Tara Devaraj, Alice Zhang, Lorenzo Leggio, Sujaya Parthasarathy, Aleksandra E Zgierska
{"title":"Glucagon-like peptide-1 receptor agonists in adults with overweight/obesity and alcohol use disorder: A retrospective cohort study.","authors":"Gretchen E Maurer, Wen-Jan Tuan, Alexandra Evans, Katherine S Chu, Tara Devaraj, Alice Zhang, Lorenzo Leggio, Sujaya Parthasarathy, Aleksandra E Zgierska","doi":"10.1016/j.ejim.2026.107270","DOIUrl":"https://doi.org/10.1016/j.ejim.2026.107270","url":null,"abstract":"<p><strong>Background: </strong>Emerging evidence suggests glucagon-like peptide-1 receptor agonists (GLP-1RAs) may improve outcomes in alcohol use disorder (AUD), which is associated with cardiovascular risk and mortality.</p><p><strong>Objective: </strong>Evaluate the association between initiation of GLP-1RAs and clinical outcomes among adults with AUD and overweight or obesity.</p><p><strong>Design: </strong>A retrospective cohort study using electronic health records from TriNetX research network, with participants enrolled between January 1, 2015 and December 31, 2024 and followed through December 31, 2025. Inverse probability of treatment weighting, based on propensity scores, balanced baseline characteristics. Weighted logistic regression models estimated the adjusted odds ratios (aORs) with 95% confidence intervals (CIs) at 1-year follow-up.</p><p><strong>Participants: </strong>Adults ≥18 years old with overweight or obesity and AUD, without prior GLP-1RAs, or cancer or non-nicotine substance use disorder diagnoses.</p><p><strong>Interventions: </strong>At least one GLP-1RA prescription issued after enrollment (Treatment cohort); none for Controls.</p><p><strong>Measures: </strong>Presence (Yes/No) of all-cause and alcohol-related hospitalizations, mortality, and major cardiovascular events (MCVE) since the GLP-1RA initiation (Treatment cohort) or post-enrollment (Control cohort).</p><p><strong>Results: </strong>Among 163,681 participants (mean age 53.7 ± 14.4 years; 35.6% female), 10,445 (6.4%) initiated GLP-1RAs. At 1-year follow-up, Treatment cohort had lower likelihood of all-cause (aOR=0.28, 95%CI: 0.28,0.29) and alcohol-related (aOR=0.20; 95%CI: 0.20,0.21) hospitalizations, death (aOR=0.20, 95%CI: 0.19,0.21), and MCVE (aOR=0.72, 95%CI: 0.71,0.74). Exploratory analyses showed that these associations remained consistent at 3 and 5 years.</p><p><strong>Conclusion: </strong>GLP-1RA initiation was associated with reduced risk of MCVE, hospitalization, and mortality among adults with AUD and overweight/obesity, supporting potential role of GLP-RAs in AUD. Prospective studies are warranted.</p>","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":" ","pages":"107270"},"PeriodicalIF":8.1,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149412511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Guillermo Ropero-Luis, Marina Melgar-Velasco, María Eugenia Carmona-Moreno, Francisco José Guerrero-Márquez
{"title":"Diuretic response in very elderly patients with acute heart failure. Author's reply.","authors":"Guillermo Ropero-Luis, Marina Melgar-Velasco, María Eugenia Carmona-Moreno, Francisco José Guerrero-Márquez","doi":"10.1016/j.ejim.2026.107278","DOIUrl":"https://doi.org/10.1016/j.ejim.2026.107278","url":null,"abstract":"","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":" ","pages":"107278"},"PeriodicalIF":8.1,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149412501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mitchell Hui, Samaneh Salimian, Ricky D Turgeon, Stephen J Greene, Robert J Mentz, Sean A Virani, Nathaniel M Hawkins, Nima Moghaddam
{"title":"Assessment of eligibility for evidence-based pharmacological therapies in acute heart failure across heart failure with reduced and non-reduced ejection fraction.","authors":"Mitchell Hui, Samaneh Salimian, Ricky D Turgeon, Stephen J Greene, Robert J Mentz, Sean A Virani, Nathaniel M Hawkins, Nima Moghaddam","doi":"10.1016/j.ejim.2026.107273","DOIUrl":"https://doi.org/10.1016/j.ejim.2026.107273","url":null,"abstract":"<p><strong>Background: </strong>Initiation of guideline-directed medical therapy (GDMT) after stabilization of an acute heart failure (AHF) episode is well-tolerated and improves outcomes. In this study, we evaluated GDMT eligibility across the spectrum of left ventricular ejection fraction (LVEF) in a contemporary AHF population.</p><p><strong>Methods: </strong>Data from VancOuver CoastAL Acute Heart Failure Audit (VOCAL-AHF) of patients discharged with AHF were retrospectively analyzed. Eligibility for GDMT was determined based on major society guidelines. Heart failure phenotypes were defined as HFrEF (LVEF ≤40%), HFmrEF (41-49%), and HFpEF (≥50%).</p><p><strong>Results: </strong>Among 1587 patients in VOCAL-AHF, there were 782 (49.3%) HFrEF, 132 (8.3%) HFmrEF, and 673 (42.4%) HFpEF. Mean age was 73±15 years and 58% were men. In HFrEF, eligibility for angiotensin receptor-neprilysin inhibitors (ARNI) was 64.4%, β-blockers 89.6%, mineralocorticoid receptor antagonists (MRA) 73.8%, and sodium-glucose cotransporter-2 inhibitor (SGLT2i) 82.2%. Overall, 64.5% were eligible for quadruple therapy. In HFmrEF, 60.6% were eligible for steroidal MRA, 66.7% for SGLT2i, and 56.8% for ARNI with 56% candidate for initiation of all three agents. Eligibility for finerenone was 62.1% based on clinical criteria and 34.1% based on strict trial criteria. Corresponding values in HFpEF were 67.4%, and 37.1%. Overall, 66.6% of patients with non-reduced EF were eligible for dual-therapy with finerenone and SGLT2i.</p><p><strong>Conclusion: </strong>Most patients with AHF, across LVEF categories, are eligible for in-hospital GDMT initiation, with a substantial proportion of those with non-reduced EF also meeting criteria for contemporary disease-modifying therapies, highlighting an important and previously underrecognized therapeutic opportunity in this population.</p>","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":" ","pages":"107273"},"PeriodicalIF":8.1,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149412500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lukas Erhart, Emanuel Steiner-Gager, Christian Baumgartner, Christoph Wegscheider, Andreas Maieron
{"title":"Risk-stratified treatment of type 1 autoimmune pancreatitis: A narrative review positioning rituximab and inebilizumab.","authors":"Lukas Erhart, Emanuel Steiner-Gager, Christian Baumgartner, Christoph Wegscheider, Andreas Maieron","doi":"10.1016/j.ejim.2026.107276","DOIUrl":"https://doi.org/10.1016/j.ejim.2026.107276","url":null,"abstract":"<p><p>Most patients with type 1 autoimmune pancreatitis, the pancreatic manifestation of IgG4-related disease, relapse within a decade of glucocorticoid cessation; the disease causes pancreatic exocrine failure, diabetes, and biliary strictures. Glucocorticoids suppress circulating plasmablasts but spare the memory B-cell compartment from which relapse appears to arise; B-cell depletion targets it. Rituximab, off-label for over a decade, is supported by observational cohorts and a meta-analysis; inebilizumab is the first targeted therapy licensed for IgG4-related disease, based on one randomised trial. This narrative review separates two decisions. First, who is likely to need B-cell depletion: any single risk feature, defined by consensus (multiorgan disease, IgG4 more than twice the upper limit of normal [ULN], diffuse pancreatic swelling) or by a quantified relapse hazard (IgG4 >4 × ULN, IgE >380 kIU/L, eosinophilia, proximal biliary strictures), may prompt depletion at diagnosis; patients without risk features may enter a time-limited glucocorticoid trial ending with a prognostic serum IgG4 measurement. Second, which agent: rituximab is the proposed default, and inebilizumab the on-label option. Whether more, or more extreme, quantified relapse predictors favour inebilizumab over rituximab is an untested hypothesis. No head-to-head trial exists, and the inebilizumab trial reported no subgroup analysis for type 1 autoimmune pancreatitis.</p>","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":" ","pages":"107276"},"PeriodicalIF":8.1,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mariantonietta Pisaturo, Pierantonio Grimaldi, Lorenzo Onorato, Chiara Cacace, Nicola Coppola
{"title":"Nucleos(t)ide analogue discontinuation strategy to achieve the functional cure for chronic hepatitis B? A systematic review and meta-analysis.","authors":"Mariantonietta Pisaturo, Pierantonio Grimaldi, Lorenzo Onorato, Chiara Cacace, Nicola Coppola","doi":"10.1016/j.ejim.2026.107274","DOIUrl":"https://doi.org/10.1016/j.ejim.2026.107274","url":null,"abstract":"<p><strong>Background: </strong>Functional cure rate is low during continuous nucleos(t)ide analog (NA) therapy, and therapy suspension has demonstrated interesting off-treatment responses.</p><p><strong>Methods: </strong>A systematic review and meta-analysis to investigate how stable, HBsAg positive-virally suppressed patients would respond to drug discontinuation in terms of HBsAg clearance, clinical remission, virological relapses, alanine-aminotransferases (ALT) flares, and necessity of therapy reintroduction were performed. Included studies were prospective, experimental and observational studies, including data on outcomes after NA discontinuation in HBV DNA negative patients with positive HBsAg, involving at least 20 patients receiving entecavir or tenofovir, published from 2008 to February 2026, written in English language.</p><p><strong>Results: </strong>A total of 28 papers (4495 patients) were included in the analysis, with low risk of bias: HBsAg clearance rate at 24, 48 and 96 weeks were of 3%, 8% and 11% (95% IC 1-8%, 4-15%, 7-15%) respectively, with low to moderate heterogeneity (I<sup>2</sup>=58.4%%, 66.5%, 47.3%); according to the HBeAg status at NA introduction, in those HBeAg negative the HBsAg clearance rates were 3%, 8% and 10% at 24, 48 and 96 weeks, respectively, while in those HBeAg positive 2.3 and 3.4% at 24 and 48 weeks, respectively. Overall a higher HBsAg clearance rate (39% at 96 weeks, 95% CI=10-78%, I<sup>2</sup>=83.3%) was described in patients with HBsAg <100 UI/ml at discontinuation. Treatment reintroduction due to virological and clinical relapse rates were 21%, 12%, and 17% at 24, 48 and 96 weeks, respectively.</p><p><strong>Conclusions: </strong>These results showed an overall low rate of HBsAg clearance after NA discontinuation, except for the patients with low HBsAg titers at this time. Thus, NA discontinuation must be balanced in the single case for the risk of virological and clinical relapses.</p>","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":" ","pages":"107274"},"PeriodicalIF":8.1,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maurizio Muscaritoli, Alessio Molfino, Carmen Gallicchio, Sara Carnevale
{"title":"Malnutrition in internal medicine wards: complementary evidence from the REPOSI and SIMI-NUTRO studies.","authors":"Maurizio Muscaritoli, Alessio Molfino, Carmen Gallicchio, Sara Carnevale","doi":"10.1016/j.ejim.2026.107265","DOIUrl":"https://doi.org/10.1016/j.ejim.2026.107265","url":null,"abstract":"","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":" ","pages":"107265"},"PeriodicalIF":8.1,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149372069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Volume status of patients with hyponatremia across the age span - results from a large prospective international study.","authors":"Emanuele Varaldo, Laura Potasso, Ewout J Hoorn, Julie Refardt, Mirjam Christ-Crain","doi":"10.1016/j.ejim.2026.107252","DOIUrl":"https://doi.org/10.1016/j.ejim.2026.107252","url":null,"abstract":"<p><strong>Background and hypothesis: </strong>Hypotonic hyponatremia is the most common electrolyte disorder in hospitalized adults and becomes increasingly prevalent with age. However, age-related differences in volume status and underlying etiologies remain poorly characterized. We aimed to assess the distribution of volume status and etiologies of hypotonic hyponatremia across the adult age span.</p><p><strong>Methods: </strong>This was a secondary analysis of the prospective Hyponatremia Intervention Trial (NCT03557957), including hospitalized adults with chronic moderate-to-severe hypotonic hyponatremia. Patients were stratified into three age groups (<65, 65-79, ≥80 years). Final volume status (hypovolemic, euvolemic, or hypervolemic) was determined at the end of hospitalization based on the complete in-hospital clinical course.</p><p><strong>Results: </strong>Overall, 1992 patients (F/M 1050/942; median age 73 [63-81] years) were analyzed. Euvolemic hyponatremia (n = 1073) predominated across all age groups and sexes, mainly due to syndrome of inappropriate antidiuresis (SIAD; n = 853). In adjusted analyses, patients aged 65-79 years (OR 1.49, 95% CI 1.19-1.88) and ≥80 years (OR 1.47, 95% CI 1.14-1.91) had higher odds of SIAD than patients aged <65 years. Volume status distribution differed across age groups (p = 0.007), driven by a higher prevalence of hypervolemic forms in patients aged ≥80 years; however, the association between age category and volume-status phenotype was attenuated and no longer statistically significant after multivariable adjustment. Hypovolemic hyponatremia (n = 613) was most commonly due to gastrointestinal sodium losses in younger patients, whereas diuretics accounted for nearly 50% of cases in those aged ≥80 years. Among patients with hypervolemic hyponatremia (n = 306), heart failure and liver insufficiency were the leading causes, with heart failure increasing and liver insufficiency decreasing across age groups.</p><p><strong>Conclusion: </strong>Euvolemic hyponatremia was the predominant form across all age groups and was mainly due to SIAD, with both older age groups showing higher adjusted odds of SIAD compared with patients aged <65 years. Age-related differences were observed in the distribution of etiologies within hypovolemic and hypervolemic hyponatremia.</p>","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":" ","pages":"107252"},"PeriodicalIF":8.1,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149358248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}